Overweight study: UBT251
Official title A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
ClinicalTrials.gov ID: NCT07395687
What this study is testing
What is UBT251?
This is an investigational injectable medicine being studied to see if it can help treat people with overweight or obesity.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to find out if UBT251 is safe and works for treating overweight or obesity.
- Who it's for
- Adults who are overweight or have obesity.
- What's involved
- Participants will receive either UBT251 or a placebo, chosen randomly, and will be monitored during the study.
- Time commitment
- The study lasts for a set period (not specified in the source) and involves regular visits to receive treatment and check-ups.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Male or female (sex at birth).
- For Japanese participants: both parents of Japanese descent.
- For Chinese participants: both parents of Chinese descent.
- For non-Asian participants: both parents of non-Asian descent (non-Asian is defined as of countries outside of Asia).
- For Part A: 18-55 years (both inclusive)
You likely can't join if
- Known or suspected hypersensitivity to study intervention(s) or related products.
- Treatment with any marketed product containing compounds with glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) or...
- Any condition, unwillingness or inability, which in the investigator's opinion might jeopardise the participant's safety or compliance with the...
See the full eligibility criteria
- Male or female (sex at birth).
- For Japanese participants: both parents of Japanese descent.
- For Chinese participants: both parents of Chinese descent.
- For non-Asian participants: both parents of non-Asian descent (non-Asian is defined as of countries outside of Asia).
- For Part A: 18-55 years (both inclusive)
- For Part B: 18-65 years (both inclusive)
- For Part C: 18-55 years (both inclusive).
- For Part A: 27.0-39.9 kilogram per meter square (kg/m\^2) (both inclusive)
- For Part B: 30.0-50.0 kg/m\^2 (both inclusive)
- For Part C: 24-34.9 kg/m\^2 (both inclusive)
- Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG), and clinical laboratory tests performed during the screening visit, as judged by the...
- Known or suspected hypersensitivity to study intervention(s) or related products.
- Treatment with any marketed product containing compounds with glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) or glucagon receptor agonism within 90 days before screening.
- Any condition, unwillingness or inability, which in the investigator's opinion might jeopardise the participant's safety or compliance with the protocol.
The study team makes the final eligibility decision.
Where it is enrolling
- Cypress, California, United States
- Overland Park, Kansas, United States
- Montreal, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Cypress, California, United States; Overland Park, Kansas, United States; Montreal, Quebec, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.